PARTNER 2 Trial

Jump to navigation Jump to search

Aortic Stenosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Aortic Stenosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Cardiac Stress Test

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Cardiac Catheterization

Aortic Valve Area

Aortic Valve Area Calculation

Treatment

General Approach

Medical Therapy

Surgery

Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty

Transcatheter Aortic Valve Replacement (TAVR)

TAVR vs SAVR
Critical Pathway
Patient Selection
Imaging
Evaluation
Valve Types
TAVR Procedure
Post TAVR management
AHA/ACC Guideline Recommendations

Follow Up

Prevention

Precautions and Prophylaxis

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

PARTNER 2 Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of PARTNER 2 Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on PARTNER 2 Trial

CDC on PARTNER 2 Trial

PARTNER 2 Trial in the news

Blogs on PARTNER 2 Trial

Directions to Hospitals Treating PARTNER 2 Trial

Risk calculators and risk factors for PARTNER 2 Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Objective

To compare the outcomes with transcatheter aortic valve replacement (TAVR) versus surgical valve replacement among intermediate-risk patients with severe aortic stenosis

Methods

Results

Conclusion

In intermediate-risk patients with severe aortic stenosis, TAVR and surgical aortic-valve replacement were associated with similar rates of death or disabling stroke (noninferiority of the transcatheter group, as compared with the surgical group).[1]

References

  1. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG (April 2016). "Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients". N. Engl. J. Med. 374 (17): 1609–20. doi:10.1056/NEJMoa1514616. PMID 27040324.